HRPT2 mutations
Showing 1 - 25 of 6,384
Pediatric Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations
Not yet recruiting
- Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF)
- +2 more
- (no location specified)
Aug 25, 2023
Advanced Solid Tumors With MAPK Pathway Mutations Trial in Nedlands (D3S-002)
Not yet recruiting
- Advanced Solid Tumors With MAPK Pathway Mutations
-
Nedlands, Western Australia, AustraliaD3 Bio Investigative Site
May 24, 2023
Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)
Not yet recruiting
- Brain Tumor
- Cancer
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) Trial (DB-OTO)
Not yet recruiting
- Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
- DB-OTO
- (no location specified)
Mar 28, 2023
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)
Not yet recruiting
- Metastatic Solid Tumor
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 12, 2023
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in
Recruiting
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
-
Canton, OhioGabrail Cancer and Research Center
Jul 21, 2023
Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT
Recruiting
- Lung Cancer Stage III
- Lung Cancer Stage IV
-
Brest, FranceChu Brest
Aug 16, 2023
NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)
Not yet recruiting
- Non-Small Cell Lung Cancer
- +2 more
-
Fairfax, VirginiaNEXT Virginia
Sep 18, 2023
Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)
Not yet recruiting
- Lung Cancer, Non-squamous, Non-small Cell
- zongertinib
- +4 more
- (no location specified)
Nov 22, 2023
Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations Trial (Axitinib 5 MG)
Available
- Clear Cell Kidney Cancer
- +2 more
- Axitinib 5 MG
- (no location specified)
Jul 3, 2023
Peripheral Nerves in Healthy Volunteers and Individuals With
Not yet recruiting
- PIEZO2-Deficiency Syndrome
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 2, 2023
HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)
Active, not recruiting
- HER2-positive Breast Cancer
- PIK3CA analysis
-
Rome, RM, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023
NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)
Recruiting
- Non-Small Cell Lung Cancer
- +5 more
- Toripalimab
- +3 more
-
Guanzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023
NSCLC Trial (Sutetinib Maleate Capsule)
Not yet recruiting
- Non-small Cell Lung Cancer
- Sutetinib Maleate Capsule
- (no location specified)
Aug 18, 2023
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers Trial (Niraparib)
Not yet recruiting
- Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
- (no location specified)
Feb 21, 2022
Solid Tumor Trial in Toronto (Binimetinib, Encorafenib)
Recruiting
- Solid Tumor
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 23, 2022
GATA2, Immunodeficiency, MDS Trial run by the National Cancer Institute (NCI) (procedure, drug, biological)
Recruiting
- GATA2
- +2 more
- Allogeneic HSCT
- +8 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 18, 2022
Interstitial Lung and Liver Disease, Infantile Liver Failure Syndrome 1, Neurologic, Endocrine and Pancreatic Disease,
Not yet recruiting
- Interstitial Lung and Liver Disease
- +3 more
- Procedure/Surgery
-
Paris, FranceHôpital Necker-Enfants Malades
Aug 22, 2022
NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
- Befotertinib + Icotinib placebo
- Icotinib + Befotertinib placebo
-
Beijing, China
- +2 more
Sep 20, 2023
Searching for Novel Germline Mutations in Lobular Breast Cancer
Recruiting
- Lobular Breast Carcinoma
- +3 more
- Illumina panel
-
Milan, ItalyEuropean Institute of Oncology
Sep 12, 2022
Duchenne Muscular Dystrophy, Exon 44 Trial in San Antonio (AOC 1044, Placebo)
Recruiting
- Duchenne Muscular Dystrophy
- Exon 44
- AOC 1044
- Placebo
-
San Antonio, TexasWorldwide Clinical Trials (Part A only)
Jan 2, 2023